Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Quanterix ( (QTRX) ) has issued an announcement.
On August 4, 2025, Quanterix Corporation announced a cooperation agreement with Kent Lake Partners LP to appoint a new independent director by December 1, 2025, and to seek shareholder approval to declassify its board. This agreement includes amending bylaws for a majority voting standard in uncontested elections and Kent Lake’s withdrawal of previous director nominations and proposals. The collaboration aims to enhance governance and focus on the company’s strategic goals, potentially benefiting stakeholders and positioning Quanterix for continued success.
The most recent analyst rating on (QTRX) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Quanterix stock, see the QTRX Stock Forecast page.
Spark’s Take on QTRX Stock
According to Spark, TipRanks’ AI Analyst, QTRX is a Neutral.
Quanterix’s overall score reflects growth potential hampered by current profitability issues. The merger and strategic initiatives are positive, but financial performance and valuation concerns weigh heavily.
To see Spark’s full report on QTRX stock, click here.
More about Quanterix
Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa® technology allows researchers to detect and quantify biomarkers at extremely low concentrations. The company has been a trusted partner to the scientific community for nearly two decades and recently expanded its capabilities with the acquisition of Akoya Biosciences, adding multiplexed tissue imaging to its portfolio.
Average Trading Volume: 746,660
Technical Sentiment Signal: Sell
Current Market Cap: $273.4M
For an in-depth examination of QTRX stock, go to TipRanks’ Overview page.